Recursion Pharmaceuticals (RXRX) EBITDA Margin (2020 - 2026)
Recursion Pharmaceuticals (RXRX) posted EBITDA Margin of 1985.55% for Q1 2026, down 551.34% on a QoQ basis from 304.84% in Q4 2025, and down 68770.0% year-over-year from N/an in Q1 2025.
Recursion Pharmaceuticals (RXRX) EBITDA Margin (2020 - 2026) Analysis & Trends
Recursion Pharmaceuticals' EBITDA Margin history runs 7 years deep, the most recent figure standing at 1985.55% for Q1 2026.
- Quarterly EBITDA Margin fell 68770.0% year-over-year to 1985.55% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 881.32% (up 7876.0% YoY) and the FY2025 annual result came in at 867.87%, down 5377.0% from the prior year.
- EBITDA Margin was 1985.55% for Q1 2026 at Recursion Pharmaceuticals, down from 304.84% in the prior quarter.
- Across five years, EBITDA Margin topped out at 304.84% in Q4 2025 and bottomed at 4042.41% in Q4 2024.
- A 5-year average of 1156.03% and a median of 862.54% in 2022 frame the typical range for EBITDA Margin.
- Annual changes were most pronounced in 2024 — EBITDA Margin plunged 313405 bps — and 2025, when it soared 373757 bps.
- Recursion Pharmaceuticals' EBITDA Margin stood at 445.91% in 2022, then sank by 104 bps to 908.36% in 2023, then plunged by 345 bps to 4042.41% in 2024, then soared by 92 bps to 304.84% in 2025, then plunged by 551 bps to 1985.55% in 2026.
- Business Quant data shows RXRX's EBITDA Margin at 1985.55% in Q1 2026, 304.84% in Q4 2025, and 3327.57% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 16.51% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 38.10% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 17.83% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 31.68% |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Recursion Pharmaceuticals | 1.59 Bn | 933.22 Mn | -6.02 Mn | -1,985.55% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1,985.55% |
| Dec 31, 2025 | -304.84% |
| Sep 30, 2025 | -3,327.57% |
| Jun 30, 2025 | -916.75% |
| Mar 31, 2025 | -1,297.85% |
| Dec 31, 2024 | -4,042.41% |
| Sep 30, 2024 | -377.10% |
| Jun 30, 2024 | -697.39% |
| Mar 31, 2024 | -698.42% |
| Dec 31, 2023 | -908.36% |
| Sep 30, 2023 | -945.12% |
| Jun 30, 2023 | -741.72% |
| Mar 31, 2023 | -575.78% |
| Dec 31, 2022 | -445.91% |
| Sep 30, 2022 | -475.48% |
| Jun 30, 2022 | -862.54% |
| Mar 31, 2022 | -1,049.71% |
| Dec 31, 2021 | -2,564.55% |
| Sep 30, 2021 | -1,831.18% |
| Jun 30, 2021 | -1,605.69% |